NCT02687087已完成不适用
Assessing the Safety and Effectiveness of Visco-ease for the Treatment of Radiotherapy Induced Xerostomia in Head and Neck Cancer Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 2
- 主要终点
- Change in GRIX Score
研究概览
简要总结
The purpose of this study is to evaluate the clinical safety and effectiveness of Visco-ease dry mouth spray for the treatment of Radiotherapy Induced Xerostomia (RIX) in head and neck cancer patients.
A parallel group double blind study design has been selected. The primary outcome is change in GRIX scores from baseline (visit 1) to end of treatment (visit 7). The primary outcome will be compared between Visco-ease and the placebo treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent
- •Male or female subjects ≥ 18 years of age
- •Subjects prescribed radiotherapy or chemoradiotherapy as primary treatment for head and neck tumours where one or more parotid glands will receive a significant dose of radiation as judged by the CI or PI during the radiotherapy planning process
排除标准
- •Subject is pregnant or breastfeeding
- •Subjects with known allergies to egg, soya, or lanolin (sheep's wool grease) based products
- •Subjects with a history of an autoimmune disease with pre-treatment xerostomia (e.g. Sjögren's syndrome) or other underlying systemic illness known to cause xerostomia independent of prior radiation therapy exposure
- •Subjects who have participated in an investigational medicinal product study within 30 days prior to signing consent
- •Any clinically significant disease or condition that may interfere with the study treatment or outcome of the study (at the discretion of the CI or PI)
- •Subjects who are unable to independently complete the questionnaire or diary
- •Subjects who are judged inappropriate for inclusion in the study by the CI or PI
- •Subjects with head and neck cancer who have had surgery to the primary site. Neck dissection alone is not an exclusion
结局指标
主要结局
Change in GRIX Score
时间窗: From baseline (Visit 1) to end of treatment (Visit 7, after 6 weeks of treatment)
The primary endpoint will compare change in GRIX scores from baseline to 6-week follow-up between the group treated with Visco-ease and the Placebo group.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Clinical Evaluation of Visco-Assisted CyPass® Micro-Stent Implantation in Patients With Open Angle GlaucomaOpen Angle GlaucomaNCT02448875Transcend Medical, Inc.192
已完成
1 期
Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® VaccineHealthyNCT01578070Viscogel AB130
已完成
不适用
Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb IschemiaPeripheral Vascular DiseasesNCT01014377VascuActive LTD15
已完成
不适用
A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and ChildrenDermatitis, AtopicNCT04740892Johnson & Johnson Consumer Inc. (J&JCI)31
已完成
2 期
Effect of Hyaluronic Acid in Wrinkles TreatmentIRCT20180228038905N1Islamic Azad University86